BridgeBio Pharma, Inc. (BBIO)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $13.02B
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Latest financial period: June 30, 2026
Filed with the SEC: August 10, 2026
Estimated earnings date: November 4, 2026
Profit #1476 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROA | -68.7% | -69.3% | -77.4% | -87.1% |
Growth #58 of 1484 companies
Payout #1117 of 1484 companies
Safety #1484 of 1484 companies
Price #1407 of 1484 companies
